HIV related stigma, perceived social support and risk of premature atherosclerosis in South Asians by Bergmann, Travis et al.
Faculty Scholarship 
2018 
HIV related stigma, perceived social support and risk of 
premature atherosclerosis in South Asians 
Travis Bergmann 
Shantanu Sengupta 
Milind P. Bhrushundi 
Hemant Kulkarni 
Partho P. Sengupta 
See next page for additional authors 
Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications 
 Part of the Public Health Commons 
Authors 
Travis Bergmann, Shantanu Sengupta, Milind P. Bhrushundi, Hemant Kulkarni, Partho P. Sengupta, and 
Icilma Fergus 
Original article
HIV related stigma, perceived social support and risk of premature
atherosclerosis in South Asians
Travis Bergmanna, Shantanu Senguptab, Milind P. Bhrushundic, Hemant Kulkarnid,
Partho P. Senguptae,*, Icilma Ferguse
aWest Virginia University, School of Public Health, Morgantown, West Virginia, United States
b Sengupta Hospital and Research Institute, Nagpur, India
cConsultant Physician, Lata Mangeshkar Hospitals, Nagpur, India
dHeart and Vascular Institute, West Virginia Medicine, Morgantown, West Virginia, United States
e Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
A R T I C L E I N F O
Article history:
Received 17 May 2018
Accepted 20 June 2018
Available online 20 June 2018
A B S T R A C T
Objective: This study sought to determine the association between social support and stigma experienced
by HIV-positive patients and presence of subclinical cardiovascular disease.
Methods: We implemented a cross sectional study in 67 HIV-positive patients and 52 controls from a
community health care center in central India. The participants underwent an in-depth survey and a
clinical and laboratory assessment of cardiovascular risk. Carotid-intimal thickness (CIMT) was used as a
marker of subclinical cardiovascular disease.
Results: On comparing the HIV and age and sex-matched control population, HIV patients had lower body
weight (P=<0.001), and lower systolic blood pressures (P = 0.002). Despite the lack of higher cardiac risk
factor prevalence and lower lipid abnormalities, HIV patients had higher right, left and average CIMT
values than controls (P < 0.001 for all). HIV patients also showed higher prevalence of abnormal CIMT (
0.9 mm) than controls (32% vs. 0%, P < 0.001). HIV patients with increased CIMT (n = 37) in comparison
with those with normal CIMT (n = 30) were more frequently males (P = 0.023), had higher systolic blood
pressures (P = 0.002), lower CD4 counts (P = 0.033) and experienced higher enacted stigma (P = 0.044). On
multivariable stepwise logistic regression, systolic blood pressure (odds ratio:1.06, P = 0.002) and stigma
score > 25th percentile value (odds ratio:3.84, P = 0.037) were independent predictors of the abnormal
CIMT.
Conclusions: HIV-positive patients from central India have a higher prevalence of abnormal CIMT as a
marker of subclinical cardiovascular disease than the general population. This predisposition to increased
cardiovascular risk may be related to complex interactions between HIV disease and stigma-related
healthcare inequalities.
© 2018 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Lower economic countries across the world are going through
an epidemiological transition with the decline of infectious and
nutritional disorders and emergence of a pandemic of non-
communicable diseases, including those related to health habits
such as diet and exercise. However, slow-smoldering infections
like HIV show paradoxical relationships with the growing
epidemiology of non-communicable diseases: On one side,
challenging socio-economic environments coupled with barriers
to accessing treatment has heightened the prevalence of HIV
globally. On the other side, HIV-positive people already on
therapies in their 30 s and 40 s are more prone to the premature
development of chronic diseases like diabetes and cardiovascular
or atherosclerotic disease.1 Not enough is understood about the
impact of existing cultural and social barriers, which are associated
with altered disease expression and increase the risk of develop-
ment of non-communicable diseases in people surviving with HIV.
Understanding the factors associated with altered disease
expression like HIV is particularly relevant for South Asian
countries such as India, where the social and economic environ-
ment is rapidly changing and nearly 2.4 million individuals are
living with HIV.2 At its core, HIV stigma is grounded in cultural
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ingrained cultural norms.3,4 Cultural barriers reduce opportunities
for disclosing HIV infection and reduce the likelihood of
preventative measures with sexual partners. They also impact
access to support and care,5 due to fear of stigma, of potential
rejection from family and friends and of loss of employment.6,7
Barriers for medication adherence, for example in refilling
prescriptions at a public pharmacy, also impose challenges for HIV-
positive people.8 Understanding these barriers is relevant because
antiretroviral therapies themselves and lack of them may
contribute to the premature development of atherosclerosis, with
coronary artery disease being one of the leading causes of death for
HIV populations.9–11
In this cross-sectional study carried out in a community center
in central India we compared: 1) the prevalence of subclinical
cardiovascular disease in comparison with the social and cultural
perceptions and the stigma experienced by patients with and
without HIV, and 2) the association of these social and behavioral
patterns and stigma with the development of subclinical
cardiovascular disease.
2. Materials and methods
2.1. Participants
The data for this cross sectional study was collected between
January 2016 and January 2017 at a tertiary health care center in
central India (Sengupta Hospital and Research Institute, Nagpur).
We recruited a convenience sample of HIV patients who were
registered and followed at Community Care Centre, Lata Man-
geshkar Hospital, Nagpur. Patients were randomly selected during
their clinic visit and given the opportunity to opt in or out of the
study, a total of 67 HIV positive patients were recruited for the
study. Inclusion criteria for the HIV-positive subjects were being
HIV-positive and over the age of 18 years. We further categorized
the cohort into groups on the basis of their treatment status and
virologic control at the baseline visit.
Control subjects were also recruited from Sengupta Hospital
and Research Institute, with inclusion criteria including being no
known diseases and over the age of 18 years. Total 52 control
participants were recruited. Exclusion criteria for the controls
included having known heart disease and being over the age of 60.
All participants were not preselected with respect to cardiovascu-
lar risk factors or coronary artery disease. The Institutional
Committee on Human Research approved this study, and all
individuals provided written informed consent before study
enrollment.
2.2. Clinical and Socio-Demographic Characteristics
Patients received a uniform questionnaire conducted by a nurse
fluent in English, Hindi, and Marathi. The survey focused on the
patient’s medical history, medication usage, symptoms of cardio-
vascular disease and presence of cardiovascular risk factors as well
as questions that explored the patient’s perceived stigma and level
of social support. HIV disease characteristics including duration of
HIV infection and current and prior antiretroviral medication were
assessed in the HIV-infected individuals.
2.3. Laboratory Assays
Blood was drawn in the fasting state and used to measure
hemoglobin, blood sugar, serum creatinine, total cholesterol, LDL
and HDL cholesterol, and triglycerides.
Carotid Artery Intima-Media Thickness: The participants were
imaged supine with their head rotated 45 away from the side
being imaged, and the images were recorded digitally using the GE
Vivid 9 system and a 10-MHz linear array probe. Intima-media
thickness (IMT) was measured in 12 segments that included the
near and far walls of the common carotid, bifurcation region and
internal carotid region on both the left and right sides. The right
and left carotid arteries were studied with the head in the midline
position and tilted upward. The probe was then adjusted to obtain
the near and far walls in a parallel orientation and then positioned
to obtain the maximal luminal diameter in the longitudinal plane.
Images were recorded digitally using a cine-loop format for
subsequent analysis using manual caliper assessment of the digital
images. Within each segment (common, internal, bifurcation
region), IMT was calculated as the average of the near and far walls
of the left and right carotid arteries. A single experienced technician
who was blinded to the subjects’ HIV status performed all the IMT
studies and caliper measurements of the digital images. Abnormal
carotid intima-media thickness (CIMT) was defined as a CIMTgreater
than 0.9 mm12 while increased CIMT was defined as age-matched
value exceeding 97.5 percentile of the normal control population.
The survey (see Supplemental Data) created for this study
combined 3 previously validated surveys: 1) the India HIV-related
Stigma Scales,13 2) the Multidimensional Scale of Perceived Social
Support,14 and the 3) NIAID AIDS Clinical Trials Group Adherence
Barriers Questionnaire.15 There were a total of 155 questions asked
in 8 groups:
1) Lab measures included those taken from the patient’s medical
record and measures taken on the day, such as weight, blood
pressure and blood draw.
2) There were six additional sections with a mix of measures:
3) Health Related Questions: answered as Yes or No.
4) Barriers to Adherence: answered using a scale of Never = 1,
Rarely = 2, Sometimes = 3, Frequently = 4.
5) Perceived Social Support: answered using a scale of Very
Strongly Agree = 1, Strongly Disagree = 2, Mildly Disagree = 3,
Neutral = 4, Mildly Agree = 5, Strongly Agree = 6, Very Strongly
Agree=7.
6) Enacted Stigma: answered as Yes or No.
7) Vicarious Stigma: answered using a scale of Never = 1, Rarely =
2, Sometimes = 3, Frequently = 4.
8) Felt Normative Scale: answered using a scale of No one = 1,
Very Few = 2, Some People = 3, Most People = 4.
9) Internalized Stigma: answered using a scale of Not at All = 1, A
Little = 2, A Fair Amount = 3, A Great Deal = 4.
3. Statistical analysis
We conducted descriptive statistics to calculate means and
standard deviations of continuous variables and frequencies of
categorical variables. Scale items were summed in order to
calculate total scale scores. Non-missing responses were included
in data analyses. We conducted independent sample t-tests for
continuous variables. Chi-square or Fisher exact test, where
appropriate, was computed to assess differences in categorical
variables. A stepwise multivariate logistic regression was per-
formed to identify independent predictors of abnormal CIMT in
HIV patients. A P < 0.05 was considered significant. Statistical
analysis was performed using MedCalc software (version 9.3.6.0,
Belgium). Scatterplot visualization for multidimensional attributes
of interest was performed using a machine-learning algorithm,
VizRank Orange 2.7.16
4. Results
The 67 HIV patients (mean age of 40  7 years and 42% male)
had been diagnosed with HIV for a mean of 10  4 years and were
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receiving highly active antiretroviral therapy (HAART) for 8  4
years. On comparing the HIV and age and sex-matched control
population (Table 1), HIV patients had lower body weight
(P=<0.001), and lower systolic blood pressures (P = 0.002). A total
of 29 (42%) HIV patients reported clinical symptoms with lower
daily time spent in exercise than controls (P < 0.001).
HIV patients and controls had no differences in prevalence of
diabetes, hypertension, tobacco use or a family history of coronary
artery disease. On comparing the laboratory investigations, HIV
participants had lower hemoglobin (P = 0.075), serum creatinine
values (P = 0.016), lower LDL (P = 0.014), and higher HDL (P = 0.013)
values. Despite the lack of a higher risk factor prevalence and lower
lipid abnormalities, HIV patients had higher right, left and average
CIMT values than controls (P < 0.001 for all). HIV patients also
showed higher prevalence of abnormal CIMT ( 0.9 mm) than
controls (32% vs. 0%, P < 0.001).
For understanding the differences in clinical features associated
with higher CIMT, we divided the CIMT patients into groups: with
normal (0.7 mm) and increased (>0.7) CIMT values. Patients with
higher CIMT were more frequently males (P = 0.023), had increased
frequency of medical illness (P = 0.048), and more frequently
experienced chest pain (P = 0.087) (Table 2). Patients with
increased CIMT also had higher systolic and diastolic blood
pressures (P = 0.002 and 0.022), and lower absolute and percentage
CD4 counts (P = 0.033 and 0.011, respectively) (Table 3). There were
no differences in perceived social support between the two groups
(Table 2). Similarly, there were no differences in vicarious stigma
and felt normative stigma scales reported by the two groups.
However, enacted stigma scale reported by patients with increased
CIMT was significantly higher than those with normal CIMT
(P = 0.044). Fig. 1 shows the distribution of HIV patients with
normal CIMT and high CIMT as per intervals of enacted stigma
index score. The proportion of HIV positive individuals with a total
enacted sigma score above 25th percentile was significantly higher
in the high CIMT group (60% vs. 86%, P = 0.013).
Fig. 2 is a linear projection graph showing the relationship
between CIMT, CD4 values and Enacted stigma. We subsequently
performed a stepwise logistic regression model including gender,
systolic blood pressure, CD4 cell count and the presence of stigma
score >25th percentile value (dichotomized). Systolic blood
pressure (odds ratio: 1.06, P = 0.011) and the presence of stigma
score > 25th percentile value (odds ratio: 3.84, P = 0.037) were the
only independent predictors of the presence of abnormal CIMT
value (Table 3).
5. Discussion
The burden of coronary artery disease (CAD) continues to rise
globally, as developing nations, including India, are adopting to
lifestyle changes that increase predisposition to cardiovascular
diseases. With the introduction of HAART, HIV has been trans-
formed to a chronic disease and infected people are living longer
and therefore experiencing the development of secondary chronic
disease such as cardiovascular diseases (CVD).10 In this cross-
sectional study, we measured carotid-intimal thickness (CIMT) as a
marker of subclinical cardiovascular disease in HIV positive
patients from central India. The principal findings were:
1) Relatively young HIV-positive subjects had significantly higher
CIMT values in comparison with age- and sex-matched healthy
general population who served as controls.
2) Patients with HIV felt lower perceived social support compared
to controls.
3) Presence of high CIMT values (>0.7 mm) in HIV patients was
associated with several high risk demographic, laboratory, and
social features like male gender, low CD4 cell counts and
increased enacted stigma scores respectively, and
4) A total of 16% of the HIV patients were not on HAART therapy
and 64% of these people had evidence of subclinical CVD and
experienced increased enacted stigma.
6. The need for screening in HIV patients
Compared to uninfected people, individuals with HIV are at a
1.5- to 2-fold greater risk of developing CVD.17 The presence of
chronic inflammation associated with HIV disease has been
correlated with risk of increased CVD. 18,19 Despite compelling
evidence that there is increased risk of CVD in HIV-positive
populations, there are no specific screening and assessment plans
for HIV populations.17 A recent European study found that stress
testing in addition to medication with stress testing and
Table 1
Clinical characteristics of HIV positive patients and control subjects.
Characteristic HIV (n = 67) Control (n = 52) P
Age (y), Mean (SD) 40.4(6.56) 37.78(9.81) 0.0851
Male, Number (%)* 28(41.79%) 28(53.84) 0.1300
Height (cm), Mean (SD) 160.72(9.37) 160.83(8.08) 0.9481
Weight (Kg) (SD) 53.34(10.36) 58.95(7.76) 0.0020
Current smokers Number (%)** 0(0) 2(3.8) 0.1888
Exercise Measure, Number (%) * 4.02  1014
10 hours 1 (1.49) 29 (55.77)
5 - <10 hours 3 (4.48) 11 (21.15)
2 - <5 hours 8 (11.94) 0 (0.00)
< 2 hours 55 (82.09) 12 (23.08)
Systolic blood pressure (mmHg), Mean (SD) 115.54(13.80) 123.14(12.24) 0.0028
Diastolic blood pressure (mmHg), Mean (SD) 74.36(11.10) 77.05(11.54) 0.2110
Hemoglobin (gm/dl), Mean (SD) 11.87(1.56) 18.67(26.71) 0.1422
Serum creatinine (mgl/dl), Mean (SD) 0.78(0.16) 0.86(0.1) 0.0077
Total Cholesterol (mg/dl), Mean (SD) 155.17(49.36) 140.65(11.74) 0.0463
LDL (mg/dl), Mean (SD) 72.51(41.98) 98.84(12.24) 0.0001
HDL (mg/dl), Mean (SD) 46.31(12.29) 40.7(3.15) 0.0025
Right Carotid IMT (mm), Mean (SD) 0.77(0.16) 0.47(0.1) 1.18  1021
Left Carotid IMT (mm), Mean (SD) 0.77(0.16) 0.48(0.13) 1.07  1017
Average CIMT (mm), Mean (SD) 0.77(0.16) 0.48(0.11) 7.14 1021
Total perceived social support, Mean (SD) 5.63 (1.00) 6.05 (0.24) 0.0039
All measures are expressed as mean (standard deviation) except when identified as n(%). * chi-square test, ** means Fisher's exact test, all continuous variables were analyzed
using the t-test
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intervention, coronary CT angiogram with medication, and
coronary CT angiogram with intervention strategies were found
to be clinically beneficial and cost-effective when compared to no
screening.20 However, developing countries like India pose several
challenges; the use of screening coronary CT angiogram or
echocardiographic stress testing may not be feasible for popula-
tion-wide screening since these tests are not easily available and
require specialized expertise. Hence the search for simple, cost-
effective strategies and identification of high risk features
associated with subclinical CVD is of paramount importance for
prevention of CVD progression in HIV-positive patients.
7. The role of CIMT as screening technique
One of the widely used and best-validated atherosclerosis
imaging techniques is the ultrasonographic measurement of
carotid intima media thickness (CIMT) – a safe, noninvasive and
cost effective method to detect subclinical and asymptomatic
atherosclerotic vascular diseases.21,22 In healthy adults the range in
distance is 0.6–0.7 mm and increases with age and is typically
greater in men. 23,24 Therefore we used a threshold of >0.7 mm for
defining increased CIMT. A threshold value of >0.9 has been used in
guidelines documents for defining abnormal CIMT and was seen in
12(18%) patients.
In the present study, HIV positive patients had significantly
higher CIMT values with nearly 37 (55%) patients having CIMT
values > 0.7 mm and 15 (22%) patients having values over 0.9 cm.
CIMT may be well suited for screening risk of CV disease in HIV
patients. Over more than two decades, CIMT has been extensively
researched and established. Moreover, several large, research-
based cohort studies have clearly indicated a relationship between
CIMT and CV events.21–29 Carotid plaque, defined as a focal
abnormal wall thickness (CIMT > 1.5 mm) or a focal thickening of
>50% of the surrounding CIMT has been shown to be a more
powerful predictor of CV risk compared with CIMT alone.
Interestingly, however, plaque formation was seen in only 2 cases
in the present study, perhaps related to the relatively young cohort
of patients where the average age was 40 years.
The findings in this study are consistent with previous reports
of increased CIMT in HIV patients compared with age-matched
control subjects.30–33 Interestingly, we observed that patients with
increased CIMT also had lower CD4 counts. This finding is also
Table 2
Clinical characteristics of High and Low CIMT groups of HIV positive patients.
NORMAL CIMT (n = 30) INCREASED CIMT (n = 37) P
Demographics
Age, years 39.36(6.92) 41.24(6.23) 0.2479
Males* 8(26.66) 20(54.05) 0.0238
Height, cm 160.44(7.49) 160.96(10.82) 0.8255
Weight, kg 51.89(10.19) 54.48(10.48) 0.3172
Duration of diagnosis (HIV), years 10.16(4.55) 9.78(3.51) 0.71
HAART, n(%) 26(86.66) 30(81.08) 0.3767
Duration of HAART therapy, years 7.72(3.8) 7.51(3.92) 0.8388
Exercise Measure: 0.7848
10 hours, n(%) 0(0) 1(2.7)
5 - <10 hours, n(%) 1(3.33) 2(5.41)
2 - <5 hours, n(%) 4(13.33) 4(10.81)
< 2 hours, n(%) 25(83.33) 30(81.08)
Medical conditions
Ongoing medical illnesses, n(%)** 3(10) 11(29.73) 0.0701
Palpitations, n(%)** 6(20) 11(29.73) 0.4098
SOB, n(%)** 1(3.33) 1(2.7) 0.9999
Edema, n(%)** 2(6.66) 2(5.4) 0.9999
Cough, n(%)** 4(13.33) 4(10.81) 0.9999
Chest Pain, n(%)** 7(23.33) 16(43.24) 0.1218
Diabetes, n(%)** 0(0) 2(5.4) 0.498
High Blood Pressure, n(%)** 0(0) 3(8.1) 0.2469
Family History of premature CAD, n(%)** 2(6.66) 0(0) 0.1967
Examination and investigations
Heart rate, beats per minute 76.39(6.33) 75.9(4.6) 0.738
SBP, mm Hg 109.92(10.51) 120.3(14.58) 0.002
DBP, mm Hg 70.92(9.29) 77.27(11.79) 0.022
Hb, gm/dl 11.52(1.39) 12.36(1.71) 0.14
Serum creatinine, mg/dl 0.79(0.12) 0.76(0.21) 0.639
Total Cholesterol, mg/dl 155.9(39.66) 154.14(62.33) 0.926
LDL, mg/dl 83.68(34.58) 57.15(48.56) 0.211
HDL, mg/dl 46.62(14.36) 45.86(9.02) 0.851
CD4 cell count, cells/mm3 655.56(302.66) 505.08(246.74) 0.033
CD4 percentage 27.43(8.15) 21.71(8.71) 0.011
Health/ Social Scales
Total Health Related 1.82(0.17) 1.78(0.16) 0.402
Total Barriers to Adherence 1.07(0.19) 1.05(0.17) 0.628
Total Perceived Social Support 5.43(1.02) 5.77(0.97) 0.177
Total Enacted Stigma Index 1.73(0.29) 1.85(0.2) 0.044
Total Vicarious Stigma 2.34(0.62) 2.08(0.74) 0.122
All measures are expressed as mean (standard deviation) except when identified as n(%).* chi-square test, ** means Fisher's exact test, all continuous variables were analyzed
using the t-test
Table 3
Multivariate logistic regression.
Variable Odds ratio 95% Confidence Interval P value
SBP 1.06 1.01-1.12 0.011
Stigma score > 25th percentile 3.84 1.08-13.67 0.037
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coherent with previous reports in which carotid IMT was shown to
be associated with classic coronary risk factors and CD4 count
< = 200, suggesting an interaction of immunodeficiency and
traditional coronary risk factors in contributing to atherosclero-
sis.34
The reason for low CD4 counts may also be related to
compliance with HAART. It has been determined that for
antiretroviral therapy to be effective adherence is required to be
>95%.35 An analysis of 569 studies found that 75.2% of HIV positive
people were optimally adherent to drug therapy.36 In three Indian
studies, adherence was determined to be 76–93%,37–39 compared
to only 55% of people in North America.40 Moreover, despite
optimal adherence there may not be a significant relationship
between adherence and viral suppression.41 This may be related to
immunological non-responders in whom the CD4 counts fail to rise
optimally despite adequate therapy.42 Irrespective of the mecha-
nism, the increased CIMT in HIV patients and low CD4 counts
suggest ongoing unsuppressed infection, which leads to enhanced
endothelial activation and inflammation despite antiretroviral
therapy.43
8. Stigma as a risk feature
The current study measured four types of stigma:
1) Internalized Stigma Scale, which refers the acceptance of
negative stereotypes about HIV as being true,44,45
2) Felt Normative Scale, which refers perceptions of the preva-
lence of HIV stigma,46
Fig. 1. Distribution of total enacted stigma index subgroups. The frequency of HIV
patients with normal CIMT (group 0, blue color) and increased CIMT (group 1, red
color) is shown as bar graphs.
Fig. 2. 2D- Linear projection graph. Lines originating from the graph origin are projections of features’ base vectors and circles represent data instances. Blue color represents
HIV patients with normal CIMT. Red represents HIV patients with increased CIMT. Size of the circle represents the %CD4 cell counts.
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3) Vicarious Stigma, hearing about other people’s discrimination
or stigma,46 and
4) Enacted Stigma, describing direct negative actions, including
but not limited to verbal harassment, discrimination or physical
assault47
In our study, HIV-positive participants felt lower perceived
social support when compared to the healthy control population,
which is consistent with previous studies.48–51 Moreover, patients
with increased CIMT reported higher Enacted Stigma. Previous
reports have suggested improving positive social support including
self-reported social support could reduce perceived HIV-related
stigma.52–54 The effects of such interventions in reducing sense of
stigma can increase one’s ability to seek care. The result of such
therapeutic interventions and their possible impact on CIMT
progression would need to be investigated in future studies.
Specifically, current guidelines suggest statins should be used by
all those with established vascular disease and among those with
type 2 diabetes or at high risk of CVD, irrespective of lipid levels.55
Moreover, existing guidelines from India recommend an aggressive
LDL target of <50 mg/dl.56 Future studies should address the value
of incorporating CIMT has a potential tool for justifying intensive
lipid therapies and evaluating the impact of such interventions in
reducing the high cardiovascular morbidity and mortality seen in
HIV-positive patients.
Stigma in Indian patients with HIV has been an area of intense
investigation, since it impacts overall disease progression. For
example, a study in West Bengal found that even without a stigma
reduction program HIV-positive people seeking care at a medical
institution felt moderate to low levels of stigma.57 In another South
Indian study it was found that 72% of people experienced severe
forms of stigma resulting into a poor quality of life.58 In another
South Indian study stigma was experienced by a higher proportion
of females than males; that study found that perceived stigma was
widespread and was suggested to be more disruptive to people’s
lives than enacted stigma.59 A relationship between enacted
stigma and felt stigma (in our study referred to as “felt normative
stigma”) that influences health care utilization, treatment adher-
ence, and overall health and well being of people with HIV has also
been reported.57 Moderate levels of stigma have also been
associated with the lack of adherence to HAART. It was found
that a reduction in stigma resulted in an increase of 5% in
adherence to HAART for men and 7% in women.60
9. Limitations and future directions
The data from the present study suggests that patients with HIV
in central India are at increased risk for premature CVD and need to
be screened and aggressively treated. Moreover, HAART need to be
optimized with close monitoring of therapeutic compliance and
responsiveness. In our study, 10 patients were not prescribed
HAART, which suggests need for wider educational programs
amongst physicians for following the recommended therapeutic
guidelines. Despite a small number of subjects, data from this pilot
study will be useful for designing larger interventional studies.
Moreover, longitudinal follow-up would be desirable to
understand the incremental value of interventions on clinical
outcomes. Caution needs to be also applied in interpreting the
control population. Since HIV test was not ethically possible to be
administered in the control population, the estimates from the
control group represent crude data for the general population.
Finally, we did not assess inflammatory markers, lipoprotein sub-
fraction analysis, subjects’ economic and educational status and
the information or the limitations of the self-reported survey,
which would need to be addressed in future investigations.
10. Conclusions
Relatively young HIV patients from central India have a higher
prevalence of abnormal CIMT as a marker of subclinical cardiovas-
cular disease than healthy general population. This predisposition
to increased cardiovascular risk is not explained by the prevalence
of traditional risk factors, and may be related to complex
interactions between chronic HIV disease and stigma-related
healthcare inequalities. These results emphasize the need for
interventions to address the stigma and promote screening
programs with positive health behavior interventions among the
high-risk HIV population in South Asian countries.
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